Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins

Journal of Lipid Research

Volumn 41, Issue 7, 2000, Pages 1035-1047

  Pruzanski, W ^a   Stefanski, E ^a   De Beer, F C ^b   De Beer, M C ^b   Ravandi, A ^a   Kuksis, A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

Functional impact; High density lipoprotein; Lipid composition; Normal and acute phase

Indexed keywords

ACUTE PHASE HIGH DENSITY LIPOPROTEIN; ACUTE PHASE PROTEIN; CHOLESTEROL ESTER; ETHANOLAMINE; HIGH DENSITY LIPOPROTEIN; INOSITOL PHOSPHATE; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID COMPOSITION; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN STRUCTURE; QUANTITATIVE DIAGNOSIS;

ACUTE-PHASE PROTEINS; ACUTE-PHASE REACTION; APOLIPOPROTEIN A-I; APOLIPOPROTEINS; ARTERIOSCLEROSIS; FATTY ACIDS; HUMANS; INFLAMMATION; LIPIDS; LIPOPROTEINS, HDL; PARTICLE SIZE; PHOSPHOLIPIDS; SERUM AMYLOID A PROTEIN; TRIGLYCERIDES;

EID: 0033911818     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Daugherty, A. 1997. Atherosclerosis: cell biology and lipoproteins. Curr. Opin. Lipidol. 8: U11-U12.
2. Libby, P., G. Sukhova, R. T. Lee, and J. K. Liao. 1997. Molecular biology of atherosclerosis. Int. J. Cardiol. 2: S23-S29.
3. Pomerantz, K. B., and D. P. Hajjar. 1989. Eicosanoids in regulation of arterial smooth muscle cell phenotype, proliferative capacity, and cholesterol metabolism. Arteriosclerosis. 9: 413-429.
4. Steinberg, D., S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924.
5. Steinberg, D., and J. L. Wiztum. 1990. Lipoproteins and atherogenesis. Current concepts. J. Am Med. Assoc. 264: 3047-3052.
6. Berliner, J. A., and J. W. Heinecke. 1996. The role oxidized lipoproteins in atherogenesis. Free Radical Biol. Med. 20: 707-727.
7. Parthasarathy, S., J. Barnett, and L. G. Fong. 1990. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta. 1044: 275-281.
8. Van Lenten, B. J., S. Y. Hama, F. C. de Beer, D. M. Stafforini, T. M. McIntyre, S. M. Prescott, B. N. La Du, A. M. Fogelman, and M. Navab. 1995. Anti-inflammatory HDL becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96: 2758-2767.
9. Baumann, H., and J. Gauldie. 1994. The acute phase response. Immunol. Today. 15: 74-80.
10. Steel, D. M., and A. S. Whitehead. 1994. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol. Today. 15: 81-88.
11. De Beer, F. C., E. A. Fagan, G. R. V. Hughes, R. K. Mallya, J. G. Lanham, and M. B. Pepys. 1982. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet. 2: 231-234.
12. Coetzee, G. A., A. F. Strachan, D. R. van der Westhuyzen, H. C. Hoppe, M. S. Jeenah, and F. C. de Beer. 1986. Serum amyloid A-containing human high density lipoprotein 3. Density, size and apolipoprotein composition. J. Biol. Chem. 261: 9644-9651.
13. Malle, E., A. Steinmetz, and J. G. Raynes. 1993. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis. 102: 131-146.
14. Steel, D. M., J. T. Rogers, M. C. de Beer, F. C. de Beer, and A. S. Whitehead. 1993. Biosynthesis of human acute-phase serum amyloid A protein (A-SAA) in vitro: the roles of mRNA accumulation, poly(A) tail shortening and translational efficiency. Biochem. J. 291: 701-707.
15. Shephard, E. G., F. C. de Beer, M. C. de Beer, M. S. Jeenah, G. A. Coetzee, and D. R. van der Westhuyzen. 1987. Neutrophil association and degradation of normal and acute-phase high-density lipoprotein 3. Biochem. J. 248: 919-926.
16. Cabana, V. G., J. R. Lukens, K. S. Rice, T. J. Hawkins, and G. S. Getz. 1996. HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J. Lipid Res. 37: 2662-2674.
17. Cabana, V. G., J. N. Siegel, and S. M. Sabesin. 1989. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J. Lipid Res. 30: 39-49.
18. Aviram, M., M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, and B. N. La Du. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paroxonase. J. Clin. Invest. 101: 1581-1590.
19. 2. Biochem. J. 309: 461-464.
20. 2 expression and inflammation: the relationship with associated disease states. J. Lipid Mediat. 8: 1-30.
21. 2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity. J. Rheumatol. 21: 252-257.
22. 2: preferential hydrolysis of acute phase HDL. J. Lipid Res. 39: 2150-2160.
23. Strachan, A. F., F. C. de Beer, D. R. van der Westhuyzen, and G. A. Coetzee. 1988. Identification of three isoform patterns of human serum amyloid A protein. Biochem. J. 250: 203-207.
24. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins of human serum. J. Clin. Invest. 43: 1345-1353.
25. Godenir, N. L., M. S. Jeenah, G. A. Coetzee, D. R. van der Westhuyzen, A. F. Strachan, and F. C. de Beer. 1985. Standardization of quantitation of serum amyloid A protein (SAA) in human serum. J. Immunol. Methods. 83: 217-225.
26. Lowry, O. H., N. J. Rosenbrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
27. Fenner, C., R. R. Trant, D. T. Mason, and J. W. Wilkman-Coffelt. 1975. Quantification of Coomassie Blue-stained proteins in polyacrylamide gels based on analyses of eluted dye. Anal. Biochem. 63: 595-602.
28. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipids from animal tissue. J. Biol. Chem. 226: 497-509.
29. Myher, J. J., A. Kuksis, and S. Pind. 1989. Molecular species of glycerophospholipids and sphingomyelins of human erythrocytes: improved method of analysis. Lipids. 24: 396-407.
30. Myher, J. J., A. Kuksis, and S. Pind. 1989. Molecular species of glycerophospholipids and sphingomyelins of human plasma: comparison to red blood cells. Lipids. 24: 408-418.
31. Myher, J. J., and A. Kuksis. 1984. Determination of plasma total lipid profiles by capillary gas-liquid chromatography. J. Biochem. Biophys. Methods. 10: 13-23.
32. Ravandi, A., A. Kuksis, and N. A. Shaikh. 1999 Glycated phosphatidylethanolamine promotes macrophage uptake of low density lipoprotein and accumulation of cholesteryl esters and triacylglycerols. J. Biol. Chem. 274: 16494-16500.
33. Morrow, J. D., T. M. Harris, Roberts, L. J. 1990. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal. Biochem. 184: 1-10.
34. Kuksis, A., J. J. Myher, K. Geher, W. C. Breckenridge, G. J. L. Ones, and J. A. Little. 1981. Lipid class and molecular species interrelationships among plasma lipoproteins of normolipemic subjects. J. Chromatogr. Biomed. Appl. 224: 1-23.
35. Skipski, V. P., M. Barclay, R. K. Barclay, V. A. Fetzer, J. J. Good, and F. M. Archibald. 1967. Lipid composition of human serum lipoproteins. Biochem. J. 104: 340-352.
36. Vieu, C., B. Jaspard, R. Barbaras, J. Manent, H. Chap, B. Perret, and X. Collet. 1996. Identification and quantification of diacylglycerols in HDL and accessibility to lipase. J. Lipid Res. 37: 1153-1161.
37. Kuksis, A., J. J. Myher, K. Gener, G. J. L. Jones, W. C. Breckenridge, T. Feather, D. Hewitt, and J. A. Littler. 1982. Decreased plasma phosphatidylcholine/free cholesterol ratio as an indicator of risk for ischemic vascular disease. Arterioslerosis. 2: 296-302.
38. Shimomura, Y., S. Sugiyama, T. Takamura, T. Kondo, and T. Ozawa. 1986. Quantitative determination of the fatty acid composition of human serum lipids by high-performance liquid chromatography. J. Chromatogr. 383: 9-17.
39. Sattler, W., H. Reicher, P. Ramos, U. Panzenhoeck, M. Hayn, H. Esterbauer, E. Malle, and G. M. Kostner. 1996. Preparation of fatty acid methyl esters from lipoprotein and macrophage lipid subclasses on thin-layer plates. Lipids. 31: 1303-1310.
40. Myher, J. J., A. Kuksis, W. C. Breckenridge, and J. A. Little. 1981. Differential distribution of sphingomyelins among plasma lipoprotein classes. Can. J. Biochem. 59: 626-636.
41. Kisilevsky, R., and L. Subrahmanyan. 1992. Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Lab. Invest. 66: 778-785.
42. 2: new discoveries. Int. J. Tissue React. 19: 41-42.
43. Cheung, M. C., A. C. Wolf, K. D. Lum, J. H. Tollefson, and J. J. Albers. 1986. Distribution and localization of lecithin:cholesterol acyltransferase and cholesteryl ester transfer activity in A-I-containing lipoproteins. J. Lipid Res. 27: 1135-1144.
44. Tall, A., D. Sharp, S. Zhong, T. Hayek, L. Masucci-Magoulas, E. M. Rubin, and J. L. Breslow. 1997. Cholesteryl ester transfer protein and atherogenesis. Ann. NY Acad. Sci. 811: 178-182.
45. Grunfeld, C., and K. R. Feingold. 1992. Tumor necrosis factor, interleukin and interferon induced changes in lipid metabolism as part of host defense. Proc. Soc. Exp. Biol. Med. 200: 224-227.
46. Feingold, K. R., and C. Grunfeld. 1992. Roles of cytokines in inducing hyperlipidemia. Diabetes. 41 (Suppl. 2): 97-101.
47. Forte, T. M., J. K. Bielicki, R. Goth-Goldstein, J. Selmek, and M. R. McCall. 1995. Recruitment of cell phospholipids and cholesterol by apolipoproteins A-II and A-I: formation of nascent apolipoprotein-specific HDL that differ in size, phospholipid composition, and reactivity with LCAT. J. Lipid Res. 36: 148-157.
48. Marathe, S., S. L. Schissel, M. J. Yellin, N. Beatini, R. Mintzer, K. J. Williams, and I. Tabas. 1998. Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implication for early atherosclerosis and ceramide-mediated cell signalling. J. Biol. Chem. 273: 4081-4088.
49. 2 only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans. J. Biol. Chem. 273: 29127-29134.
50. Schissel, S. L., X-C. Jiang, J. Tweedie-Hartman, T-S. Jeong, E. H. Camejo, J. Najib, J. H. Rapp, K. J. Williams, and I. Tabas. 1998. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. J. Biol. Chem. 273: 2738-2746.
51. Berliner, J., N. Leitinger, A. Watson, J. Huber, A. Fogelman, and M. Navab. 1997. Oxidized lipids in atherogenesis: formation, destruction and action. Thromb. Haemostasis. 78: 195-199.
52. Watson, A. D., G. Subbanagounder, D. E. S. Welsbie, K. F. Faull, M. Navab, M. E. Jung, A. M. Fogelman, and J. A. Berliner. 1999. Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein. J. Biol. Chem. 274: 24787-24798.
53. Yamakawa, T., S. Egushi, Y. Yamakawa, E. D. Motley, K. Numaguchi, H. Utsunomiya, and T. Inagami. 1998. Lysophosphatidylcholine stimulates MAP kinase activity in rat vascular smooth muscle cells. Hypertension. 31: 248-253.
54. Fang, X., S. Gibson, M. Flowers, T. Furui, R. C. Bast, Jr., and G. B. Mills. 1997. Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. J. Biol. Chem. 272: 13683-13689.
55. Kume, N., M. I. Cybulsky, and M. A. Gimbrone, Jr. 1992. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90: 1138-1144.
56. Quinn, M. T., S. Parthasarathy, and D. Steinberg. 1988. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl. Acad. Sci. USA. 85: 2805-2809.
57. Yagi, K., S. Komura, H. Kojima, Q. Sun, N. Nagata, N. Ohishi, and M. Nishikimi. 1996. Expression of human phospholipid hydroperoxide glutathione peroxidase gene for protection of host cells from lipid hydroperoxide-mediated injury. Biochem. Biophys. Res. Commun. 219: 486-491.
58. Kaneko, T., N. Baba, and M. Matsuo. 1996. Cytotoxicity of phosphatidylcholine hydroperoxides is exerted through decomposition of fatty acid hydroperoxide moiety. Free Radical Biol. Med. 21: 173-179.
59. Bielicki, J. K., and T. M. Forte. 1999. Evidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity. J. Lipid Res. 40: 948-954.
60. Navab, M., S. Y. Hama, G. P. Hough, C. C. Hedrick, R. Sorenson, B. N. La Du, J. A. Kobashigawa, G. C. Fonarow, J. A. Berliner, H. Laks, and A. M. Fogelman. 1998. High density associated enzymes: their role in vascular biology. Curr. Opin. Lipidol. 9: 449-456.
61. Aviram, M., M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, C. L. Bisgaier, R. S. Newton, and B. La Du. 1999. Human serum paroxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biol. Med. 26: 892-904.
62. 2 in atherosclerosis. 2. Potential involvement of biologically active oxidized phospholipids. Arteriosler. Thromb. Vasc. Biol. 19: 1291-1298.
63. 2. Arterioscler. Thromb. Vasc. Biol. 19: 1284-1290.
64. Acton, S., A. Rigotti, K. T. Landschulz, S. Xu, H. H. Hobbs, and M. Krieger. 1996. Identification of scavenger receptors SR-BI as high density lipoprotein receptor. Science. 271: 518-520.
65. Rigotti, A., S. L. Acton, and M. Krieger. 1995. The class B scavenger receptors SR-BI and CD-36 are receptors for anionic phospholipids. J. Biol. Chem. 270: 16221-16224.
66. Xu, S., M. Laccotripe, X. Huang, A. Rigotti, V. I. Zannis, and M. Krieger. 1997. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J. Lipid Res. 38: 1289-1298.